Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25741233 | 0.93 | FOLH1 (0.52) | FOLH1EGFRLCKFFAR1CA1 | |
| SCHEMBL27303602 | 0.93 | FOLH1 (0.52) | FOLH1EGFRLCKFFAR1CA1 | |
| SCHEMBL29340370 | 0.92 | FOLH1 (0.51) | FOLH1EGFRLCKFFAR1CA1 | |
| SCHEMBL25801389 | 0.91 | FOLH1 (0.52) | FOLH1EGFRLCKFFAR1CA1 | |
| SCHEMBL22131080 | 0.91 | FOLH1 (0.52) | FOLH1BACE1 | |
| SCHEMBL18292001 | 0.90 | FOLH1 (0.54) | FOLH1FFAR1FFAR4BACE1 | |
| SCHEMBL18811743 | 0.90 | FOLH1 (0.56) | FOLH1CA1CA2CA12CA9 | |
| SCHEMBL25797889 | 0.90 | FOLH1 (0.49) | FOLH1EGFRLCKFFAR1CA1 | |
| SCHEMBL25573716 | 0.90 | FOLH1 (0.48) | FOLH1FFAR1CA1CA2KEAP1 | |
| SCHEMBL23940424 | 0.89 | FOLH1 (0.49) | FOLH1FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133780-A1 | CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | Technische Universität München (DE) | 2024-06-27 | — | — | WO | claimed |
| EP-4389150-A1 | CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | Technische Universität München (DE) | 2024-06-26 | — | — | EP | claimed |
| EP-4288116-A1 | PSMA-TARGETING LIGANDS FOR MULTIMODAL APPLICATIONS | Stichting Radboud universitair medisch centrum (NL) | 2023-12-13 | — | — | EP | claimed |
| EP-3763394-B1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | ISOTOPIA MOLECULAR IMAGING LTD (IL) | 2023-11-08 | — | — | EP | claimed |
| US-11180511-B2 | Diagnosis, treatment and prevention of neurotensin receptor-related conditions | FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG; UNIVERSITÄTSKLINIKUM ERLANGEN (DE) | 2021-11-23 | — | — | US | claimed |
| EP-3763394-A1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | Isotopia Molecular Imaging Ltd (IL) | 2021-01-13 | — | — | EP | claimed |
| US-20200377523-A1 | DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-12-03 | — | — | US | claimed |
| US-20200138985-A1 | KIT FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | Isotopia Molecular Imaging Ltd. (IL) | 2020-05-07 | — | — | US | claimed |
| US-20160256579-A1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | Isotopia Molecular Imaging Ltd. (IL) | 2016-09-08 | — | — | US | claimed |
| EP-3064224-A1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | Isotopia Molecular Imaging Ltd (IL) | 2016-09-07 | — | — | EP | claimed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4455159-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024133780-A1 | CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | Technische Universität München (DE) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389150-A1 | CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | Technische Universität München (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-20130136691-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2013-05-30 | — | — | US | disclosed |
| US-20110250133-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2011-10-13 | — | — | US | disclosed |
| EP-2291075-A2 | GASTRIN RELEASING PEPTIDE COMPOUNDS | Bracco Imaging S.p.A (IT) | 2011-03-09 | — | — | EP | disclosed |
| WO-2010066051-A1 | THIOL-NOTA DERIVATIVES FOR KIT 68GA RADIOLABELING | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2010-06-17 | — | — | WO | disclosed |
| WO-2009143101-A2 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136691-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | GRPR, GIPR, GHRHR | FOLH1 804/4885EGFR 115/4885LCK 3692/4885 |
| US-20160256579-A1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | KLK3, FOLH1, PSMA7 | FOLH1 2/4885EGFR 450/4885LCK 2615/4885 |
| US-11180511-B2 | Diagnosis, treatment and prevention of neurotensin receptor-related conditions | NTSR1, NTSR2, NPSR1 | FOLH1 275/4885EGFR 531/4885LCK 1292/4885 |
| US-20200138985-A1 | KIT FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | KLK3, FOLH1, KIT | FOLH1 2/4885EGFR 438/4885LCK 2385/4885 |
| US-20110250133-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | GRPR, GIPR, GHRHR | FOLH1 804/4885EGFR 115/4885LCK 3692/4885 |
| US-20200377523-A1 | DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS | NTSR1, NTSR2, NPSR1 | FOLH1 275/4885EGFR 531/4885LCK 1292/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | FOLH1 335/4885EGFR 144/4885LCK 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.